Novaliq receives positive CHMP opinion for Vevizye in treatment of dry eye disease

News
Article

The positive opinion comes with the recommendation that ciclosporin 0.1% be granted marketing authorisation in the European Union

A person at a desk prepares to open a manila file folder with "OFFICIAL" stamped on it. Image credit: ©Markus Bormann – stock.adobe.com

In the ESSENCE-1 and ESSENCE-2 clinical trials, Vevizye demonstrated improvements in patients with moderate and severe DED. Image credit: ©Markus Bormann – stock.adobe.com

Novaliq announced its therapeutic candidate ciclosporin 0.1% solution (Vevizye) has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the treatment of dry eye disease (DED), in adult patients which have not improved despite treatment with tear substitutes.

The positive opinion from the CHMP comes with the recommendation that Vevizye be granted marketing authorisation in the European Union.

Dry eye treatments are limited in Europe, as only one drug therapy is approved in the EU and is restricted to treatment of severe keratitis associated with DED.1

Novaliq submitted the Marketing Authorisation Application (MAA) for Vevizye in July 2023. The positive opinion is based on a comprehensive data package submitted by Novaliq, containing more than 1,500 patients with moderate to severe DED.1,2

Professor José M. Benítez del Castillo, PhD, Chair of the Department of Ophthalmology at University Complutense Madrid, Spain, discussed the news in a press release from Novaliq.

“Clinical data for Vevizye showed clinically meaningful improvements of the ocular surface as early as 2 weeks, combined with an excellent tolerability profile and high treatment satisfaction,” said Benítez del Castillo. ”I am enthusiastic that there will be a new treatment option addressing these important aspects of a dry eye therapy in Europe.”

Vevizye, which was developed under the name CyclASol, is a ciclosporin 0.1% solution, free of oils, surfactants and preservatives. Novaliq states that “this unique water-free therapy unfolds the full potential of ciclosporin to efficiently treat dry eye disease [which is] fast and comfortable for patients.”

In the ESSENCE-1 and ESSENCE-2 clinical trials, Vevizye demonstrated clinically meaningful and statistically significant improvements in patients with moderate and severe DED. A statistically significant reduction in total corneal fluorescein staining score favoring Vevizye was seen as early as day 15, while up to 71.6% of patients responded within 4 weeks with a clinically meaningful improvement in total corneal fluorescein staining.

Sonja Krösser, PhD, Vice President Medical Science and Regulatory Affairs for Novaliq said the “positive CHMP opinion for Vevizye marks a major achievement and the pinnacle of our extensive research in dry eye disease therapies. If the marketing authorisation in the EU is formally granted, this unique water-free ciclosporin therapy will be the first medicinal therapy approved to treat dry eye disease in the US and EU.”

Vevye was approved by the US Food and Drug Administration in May 2023, and launched in the US by Harrow.

References:

  1. Novaliq Receives Positive CHMP Opinion FOR Vevizye® in Dry EYE Disease. Press Release; July 29, 2024. Accessed July 29, 2024. https://www.novaliq.com/press-releases/2024/07/29/novaliq-receives-positive-chmp-opinion-for-vevizye-in-dry-eye-disease/
  2. EMA Press Release. Vevizye. Released July 25, 2024. Accessed July 29, 2024. https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-vevizye_en.pdf

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.